Aldeyra Stock Performance
| ALDX Stock | USD 4.85 0.04 0.83% |
The firm shows a Beta (market volatility) of 1.8, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Aldeyra will likely underperform. At this point, Aldeyra has a negative expected return of -0.1%. Please make sure to confirm Aldeyra's skewness, and the relationship between the total risk alpha and day median price , to decide if Aldeyra performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Aldeyra has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's fundamental indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Actual Historical Performance (%)
One Day Return 0.83 | Five Day Return (1.02) | Year To Date Return 37.01 | Ten Year Return (35.42) | All Time Return (32.64) |
1 | Insider Trading | 08/30/2024 |
2 | Aldeyra Therapeutics Announces Executive Team Changes - TipRanks | 09/03/2024 |
3 | Disposition of 48021 shares by Brady Todd C of Aldeyra at 0.552 subject to Rule 16b-3 | 09/16/2024 |
4 | Aldeyra To Make Second Bid For FDA Approval Of Dry Eye Disease Drug - RTTNews | 09/19/2024 |
5 | Perceptive Advisors LLC Acquires 682,265 Shares of Aldeyra Therapeutics, Inc - MarketBeat | 09/30/2024 |
6 | Aldyera therapeutics director Nancy Miller-Rich buys 10,446 in stock | 10/22/2024 |
7 | Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference | 11/14/2024 |
8 | Aldeyra announces FDA acceptance of resubmitted reproxalap application | 11/18/2024 |
9 | Aldeyra Therapeutics Refiles NDA for Innovative Dry Eye Drug Reproxalap | 11/19/2024 |
| Begin Period Cash Flow | 144.4 M |
Aldeyra |
Aldeyra Relative Risk vs. Return Landscape
If you would invest 544.00 in Aldeyra on August 25, 2024 and sell it today you would lose (59.00) from holding Aldeyra or give up 10.85% of portfolio value over 90 days. Aldeyra is currently does not generate positive expected returns and assumes 3.8086% risk (volatility on return distribution) over the 90 days horizon. In different words, 33% of stocks are less volatile than Aldeyra, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aldeyra Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aldeyra's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aldeyra, and traders can use it to determine the average amount a Aldeyra's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0275
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALDX |
Estimated Market Risk
| 3.81 actual daily | 33 67% of assets are more volatile |
Expected Return
| -0.1 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Aldeyra is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aldeyra by adding Aldeyra to a well-diversified portfolio.
Aldeyra Fundamentals Growth
Aldeyra Stock prices reflect investors' perceptions of the future prospects and financial health of Aldeyra, and Aldeyra fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aldeyra Stock performance.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.23 | ||||
| Current Valuation | 191.68 M | ||||
| Shares Outstanding | 59.55 M | ||||
| Price To Earning | (4.44) X | ||||
| Price To Book | 3.39 X | ||||
| EBITDA | (35.21 M) | ||||
| Net Income | (37.54 M) | ||||
| Cash And Equivalents | 163.83 M | ||||
| Cash Per Share | 2.80 X | ||||
| Total Debt | 15.66 M | ||||
| Debt To Equity | 0.1 % | ||||
| Current Ratio | 7.83 X | ||||
| Book Value Per Share | 1.43 X | ||||
| Cash Flow From Operations | (30.33 M) | ||||
| Earnings Per Share | (0.75) X | ||||
| Market Capitalization | 288.82 M | ||||
| Total Asset | 148.33 M | ||||
| Retained Earnings | (394.26 M) | ||||
| Working Capital | 125.55 M | ||||
| Current Asset | 28.09 M | ||||
| Current Liabilities | 2.12 M | ||||
About Aldeyra Performance
Evaluating Aldeyra's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Aldeyra has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Aldeyra has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -4.1 K | -4.3 K | |
| Return On Tangible Assets | (0.25) | (0.27) | |
| Return On Capital Employed | (0.34) | (0.36) | |
| Return On Assets | (0.25) | (0.27) | |
| Return On Equity | (0.31) | (0.30) |
Things to note about Aldeyra performance evaluation
Checking the ongoing alerts about Aldeyra for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aldeyra help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aldeyra generated a negative expected return over the last 90 days | |
| Aldeyra has high historical volatility and very poor performance | |
| Net Loss for the year was (37.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Aldeyra currently holds about 163.83 M in cash with (30.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.8. | |
| Aldeyra has a frail financial position based on the latest SEC disclosures | |
| Roughly 62.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Aldeyra Therapeutics Refiles NDA for Innovative Dry Eye Drug Reproxalap |
- Analyzing Aldeyra's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aldeyra's stock is overvalued or undervalued compared to its peers.
- Examining Aldeyra's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aldeyra's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aldeyra's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aldeyra's stock. These opinions can provide insight into Aldeyra's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Aldeyra Stock Analysis
When running Aldeyra's price analysis, check to measure Aldeyra's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aldeyra is operating at the current time. Most of Aldeyra's value examination focuses on studying past and present price action to predict the probability of Aldeyra's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aldeyra's price. Additionally, you may evaluate how the addition of Aldeyra to your portfolios can decrease your overall portfolio volatility.